Ashish Premkumar1, Annie M Dude2, Lisa B Haddad3, Lynn M Yee2. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Feinberg School of Medicine, Northwestern University, 250 E. Superior Street, Chicago, IL 60611, USA. Electronic address: ashish.premkumar@northwestern.edu. 2. Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Feinberg School of Medicine, Northwestern University, 250 E. Superior Street, Chicago, IL 60611, USA. 3. Department of Gynecology and Obstetrics, Emory University School of Medicine, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303, USA.
Abstract
OBJECTIVE: To assess if there is a relationship between use of combined antiretroviral therapy among pregnant women living with HIV and hypertensive disorders of pregnancy (HDP). DESIGN: Due to the heterogeneity of study designs in the literature and the utilization of different outcome measures in regards to assessing the presence of HDP, a systematic review was performed. METHODS: ClinicalTrials.gov and MEDLINE, via PubMed, EMBASE, Scopus, CINAHL, ProQuest Dissertations & Theses Global, EBSCOHost, DARE, and the Cochrane Library, were queried from January 1997 to October 2017. Studies were included if they reported HDP and focused on pregnant women living with HIV who used combined antiretroviral therapy. The Cochrane Collaboration's tool for assessment of risk of bias and the U.S. Preventive Services Task Force grading scale were used to assess the studies. RESULTS: Of 1055 abstracts, 28 articles met inclusion criteria. The data are marked by multiple biases and poor study design. All studies demonstrate an increased risk of HDP among pregnant women living with HIV who used combined antiretroviral therapy when compared to seropositive pregnant women not using antiretroviral therapy. Three studies suggest protease inhibitors may be associated with a higher risk of HDP. CONCLUSION: Despite all studies indicating a higher frequency of HDP among pregnant women living with HIV using combined antiretroviral therapy when compared with seropositive pregnant women not using antiretroviral therapy, the quality of the studies is mixed, necessitating further research.
OBJECTIVE: To assess if there is a relationship between use of combined antiretroviral therapy among pregnant women living with HIV and hypertensive disorders of pregnancy (HDP). DESIGN: Due to the heterogeneity of study designs in the literature and the utilization of different outcome measures in regards to assessing the presence of HDP, a systematic review was performed. METHODS: ClinicalTrials.gov and MEDLINE, via PubMed, EMBASE, Scopus, CINAHL, ProQuest Dissertations & Theses Global, EBSCOHost, DARE, and the Cochrane Library, were queried from January 1997 to October 2017. Studies were included if they reported HDP and focused on pregnant women living with HIV who used combined antiretroviral therapy. The Cochrane Collaboration's tool for assessment of risk of bias and the U.S. Preventive Services Task Force grading scale were used to assess the studies. RESULTS: Of 1055 abstracts, 28 articles met inclusion criteria. The data are marked by multiple biases and poor study design. All studies demonstrate an increased risk of HDP among pregnant women living with HIV who used combined antiretroviral therapy when compared to seropositive pregnant women not using antiretroviral therapy. Three studies suggest protease inhibitors may be associated with a higher risk of HDP. CONCLUSION: Despite all studies indicating a higher frequency of HDP among pregnant women living with HIV using combined antiretroviral therapy when compared with seropositive pregnant women not using antiretroviral therapy, the quality of the studies is mixed, necessitating further research.
Authors: Anna Suy; Esteban Martínez; Oriol Coll; Montserrat Lonca; Montserrat Palacio; Elisa de Lazzari; María Larrousse; Ana Milinkovic; Sandra Hernández; José L Blanco; Josep Mallolas; Agathe León; Juan A Vanrell; José M Gatell Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: R C Wimalasundera; N Larbalestier; J H Smith; A de Ruiter; S A McG Thom; A D Hughes; N Poulter; L Regan; G P Taylor Journal: Lancet Date: 2002-10-12 Impact factor: 79.321
Authors: Athena P Kourtis; Pooja Bansil; Melissa McPheeters; Susan F Meikle; Samuel F Posner; Denise J Jamieson Journal: AIDS Date: 2006-09-11 Impact factor: 4.177
Authors: K Boer; J F Nellen; D Patel; S Timmermans; C Tempelman; M Wibaut; M A Sluman; M E van der Ende; M H Godfried Journal: BJOG Date: 2007-02 Impact factor: 6.531
Authors: Michele K Saums; Caroline C King; Jenna C Adams; Anandi N Sheth; Martina L Badell; Marisa Young; Lynn M Yee; Ellen G Chadwick; Denise J Jamieson; Lisa B Haddad Journal: Obstet Gynecol Date: 2019-12 Impact factor: 7.661
Authors: Brigid E O'Brien; Paige L Williams; Yanling Huo; Deborah Kacanek; Ellen G Chadwick; Kathleen M Powis; Katharine Correia; Lisa B Haddad; Lynn M Yee; Nahida Chakhtoura; Chi Dola; Russell B Van Dyke Journal: J Acquir Immune Defic Syndr Date: 2020-11-01 Impact factor: 3.771
Authors: Jennifer E Balkus; Moni Neradilek; Lee Fairlie; Bonus Makanani; Nyaradzo Mgodi; Felix Mhlanga; Clemensia Nakabiito; Ashley Mayo; Tanya Harrell; Jeanna Piper; Katherine E Bunge Journal: PLoS One Date: 2021-03-31 Impact factor: 3.240